Drug Target Review2025-02-13T08:00:56
An AI tool has identified adalimumab, a drug used for arthritis and Crohn’s disease, as a life-saving treatment for rare Castleman’s disease (iMCD). This finding offers hope for patients with the condition.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2026-08-17T14:16:00Z
Contributor Dr Rab Prinjha, Drug Target Review
2023-03-20T13:41:33
Sponsored by Bio-Techne
2026-03-25T15:00:00
Sponsored by Yokogawa
2026-08-11T07:02:00
Contributor Professor Joseph C. Wu, Drug Target Review
2026-05-25T07:00:00
Contributor Professor Neville Sanjana
2026-03-11T14:00:00
Sponsored by Merck
2026-06-04T07:05:00
Author Graham Craig
Site powered by Webvision Cloud